Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label roll-over study of long-term safety of lenvatinib or comparator regimens
2017-003668-11Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib in Nonhematologic neoplasms, lymphoma, thyroid cancer and 1 more (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Long-term safety (TEAEs and SAEs). Started Mar 2018; status: completed.
02
Drugs
lenvatinib
03
Conditions
Nonhematologic neoplasmslymphomathyroid cancercancer
Beyond the preview
Go deeper on 2017-003668-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003668-11.